Bioregnum channel feed

Q3 snap­shot: The IPO mar­ket shows fresh signs of im­prove­ment, but the biotech crunch con­tin­ues to bite

Last year

Ex­clu­sive: As­traZeneca signs off on a ‘car­bon neg­a­tive’ new biotech build­ing for one of its lat­est buy­outs

Last year
Pharma

Did I ever tell you the one about the drunk­en biotech awards pro­gram I host­ed at a Chica­go bar?

Last year
Editor's note

Astel­las builds its R&D foot­print in Cam­bridge/Boston with an add-on for labs, of­fices

Last year

As SQZ faced a fi­nal reck­on­ing, a fate­ful board de­ci­sion steered the com­pa­ny to a quick and bru­tal endgame

Last year

The vet­er­an crew at Medicxi is back with a new $400M fund and an up­beat as­sess­ment of what's com­ing

Last year
Financing
Startups

Fa­heem Has­nain gets a $212M stake to­geth­er for his big PhI­II gam­ble — here’s why in­vestors are let­ting it ride

Last year
Deals

A small Swiss biotech tack­les a huge glob­al health is­sue with a hand­off from GSK. But can it make any mon­ey from it?

Last year
Deals

Pfiz­er, Flag­ship al­ly on a $100M cash launch of a drug dis­cov­ery ex­pe­di­tion

Last year
Deals

Bill Haney adds a match­ing $100,000 con­tri­bu­tion to Kris­ten Hege's ad­ven­tur­ous fundrais­er back­ing women sci­en­tists

Last year

Af­ter eject­ing out of Bris­tol My­ers R&D, Ru­pert Vessey lands at the top sci­ence post at a buzzy Flag­ship

Last year
People

Tes­sa en­joyed big back­ers, great sci­ence and world-class am­bi­tion. So what did we learn from its col­lapse?

Last year
Cell/Gene Tx

The H1 pic­ture: Biotech’s vi­tal signs show some life — with one big ex­cep­tion

Last year

The End­points 11 is back: Nom­i­nate your fa­vorite biotech for our an­nu­al re­port on the most promis­ing star­tups in the world

Last year

As­traZeneca en­lists an up­start Chi­na biotech part­ner in the wake of an R&D set­back

Last year
Deals
China

Bris­tol My­ers of­fers a $100,000 vote of sup­port for Kris­ten Hege's ad­ven­tur­ous fundrais­ing cam­paign

Last year

Who's con­fi­dent­ly in­vest­ing in biotech star­tups dur­ing these tense days? We've got some an­swers

Last year

Amit Mun­shi has more than $300M and a start­up CSO out to pi­o­neer next-gen RNA ther­a­peu­tics. Once again, he’s think­ing big

3 years ago
Financing

Ex-FDA neu­ro chief Bil­ly Dunn is tak­ing a spin through the re­volv­ing door with bio­phar­ma — and that's a prob­lem

3 years ago
FDA+

The E100: Ex­tend­ing run­ways, dump­ing drugs, fac­tor­ing in a bank­ing cri­sis and grap­pling with the IRA — there's a lot for biotech ex­ecs to deal with

3 years ago
Special

When is a pre­clin­i­cal drug worth a moth­er lode of cash? This top 20 list of­fers a few an­swers

3 years ago
Deals
R&D

Re­mem­ber that record biotech IPO par­ty in 2018? There was no ‘hap­pi­ly ever af­ter’

3 years ago
People

In a sur­prise shift, Tony Coles taps his suc­ces­sor as CEO of Bain start­up Cerev­el

3 years ago
People

J&J goes block­buster hunt­ing (again) with $245M cash up­front for next-gen CAR-T

3 years ago
Deals
First page Previous page 12345 Next page Last page
A service from the Financial Times